MediciNova says NIH awards research griant to UCLA for MN-166 trial
MediciNova announced that the National Institute on Alcohol Abuse and Alcoholism, which is part of the National Institutes of Health, will fund a Phase 2b clinical trial to evaluate MN-166 as a potential treatment to decrease alcohol consumption in treatment-seeking patients with alcohol use disorder. This study is a randomized, double-blind, placebo-controlled outpatient trial which will enroll up to 132 patients. The NIAAA R01 research funding was awarded to Principal Investigator Dr. Lara Ray, PhD, ABPP, at the University of California, Los Angeles' Departments of Psychology, and Psychiatry and Biobehavioral Sciences Brain Research Institute, based on her recent findings that MN-166 was associated with mood improvements during stress- and alcohol-cue exposures, significantly decreased alcohol-induced stimulation and positive mood, decreased overall craving for alcohol in non-treatment seeking volunteers, and was safe and well-tolerated. MediciNova will provide drug supply and regulatory support for the clinical trial.